Following Abstract by Cora Stenberg has been accepted for Poster presentation (display) at ESMO 2024, to be held in Barcelona, 13-17 September 2024: Evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant (NAD) therapy.